Jiangsu Hengrui Medicine Co., Ltd. specializes in the research, development, manufacture and marketing of pharmaceutical products. The activity is organized primarily around 5 families of products: - anti-tumor drugs (No. 1 Chinese); - Anesthetic drugs; - contrast agents: used in medical imaging; - anti-inflammatory drugs; - drugs for the treatment of cardiovascular diseases.

Employees

19,611

Sector

Pharmaceuticals

Calendar

2025-04-20 - Q1 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
25-01-20	45.13 ¥	+1.37%	35,398,010
25-01-20	44.52 ¥	+3.92%	55,860,290
25-01-17	42.84 ¥	-0.14%	20,061,220
25-01-16	42.90 ¥	-2.23%	31,015,770
25-01-15	43.88 ¥	-0.93%	18,496,450

End-of-day quote Shanghai S.E., January 20, 2025

More quotes

Income Statement and Estimates

income-statement-evolution-chart JIANGSU-HENGRUI-MEDICINE-

More financial data

Ratings

Trading Rating

Investor Rating

ESG MSCI

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

44.52CNY

Average target price

59.81CNY

Spread / Average Target

+34.34%

Consensus

Profit revisions

estimates-change-chart JIANGSU-HENGRUI-MEDICINE-

Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart JIANGSU-HENGRUI-MEDICINE-

Company calendar

End-of-day quote Shanghai S.E. Other stock markets 2025-01-21			5-day change	1st Jan Change
45.13 ^CNY	+1.37%		+5.42%	-1.68%

Jan. 17	Jiangsu Hengrui Medicine Gets Approval to Conduct Clinical Trials for Two Anti-tumor Drugs	MT
Jan. 14	Jiangsu Hengrui Medicine Gets China Clinical Trial Approval for Anti-Tumor Injection	MT

Capitalization	287B 39.3B 37.8B 35.68B 31.95B 56.28B 3,388B 62.77B 434B 161B 1,398B 147B 144B 6,119B	P/E ratio 2024 *	47.7x	P/E ratio 2025 *	43.7x
Enterprise value	263B 36.05B 34.67B 32.73B 29.31B 51.62B 3,108B 57.57B 398B 147B 1,282B 135B 132B 5,612B	EV / Sales 2024 *	9.71x	EV / Sales 2025 *	8.67x
Free-Float	52.38%	Yield 2024 *	0.52%	Yield 2025 *	0.57%

Jiangsu Hengrui Medicine Gets Approval to Conduct Clinical Trials for Two Anti-tumor Drugs	Jan. 17	MT
Jiangsu Hengrui Medicine Gets China Clinical Trial Approval for Anti-Tumor Injection	Jan. 14	MT
Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics Report Positive Topline Data from 8 Mg Dose of Phase 2 Obesity Trial of GLP-1/GIP Receptor Dual Agonist HRS9531	Jan. 13	CI
Jiangsu Hengrui Medicine Gets Approval to Conduct Clinical Trials on Anti-Tumor Drug	Jan. 13	MT
Jiangsu Hengrui Medicine Gets Drug Registration for Cardiovascular Drug	Jan. 12	MT
Chinese Drug Regulator Accepts Hengrui Medicine's Marketing Application for SHR4640 Tablets	Jan. 09	MT
Chinese Shares Close Mixed Amid Weak Yuan; Mabwell (Shanghai) Bioscience Down 2%	Jan. 08	MT
Jiangsu Hengrui Medicine Files for Hong Kong Listing	Jan. 07	MT
Jiangsu Hengrui Medicine Gets Approval to Conduct Clinical Trials for HRS-6768 Injection	Jan. 06	MT
Tranche Update on Jiangsu Hengrui Medicine Co., Ltd.'s Equity Buyback Plan announced on May 15, 2024.	Jan. 02	CI
IDEAYA Biosciences, Inc. Enters Exclusive License with Jiangsu Hengrui Pharmaceuticals Co., Ltd. for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors	Dec. 29	CI
Hengrui Medicine Gets Nod to Trial Prostate Cancer Drug	Dec. 25	MT
Hengrui Medicine Subsidiaries Receive Approval for Anti-Tumor Drug Trial	Dec. 22	MT

SPDB International HK Starts Jiangsu Hengrui Pharmaceuticals at Buy with 61 Yuan Price Target	Nov. 27	MT
Nomura Adjusts Jiangsu Hengrui Medicine's Price Target to 50.17 Yuan From 48.32 Yuan, Keeps at Neutral	24-10-22	MT
Nomura Adjusts Jiangsu Hengrui Medicine's Price Target to 48.32 Yuan From 51.12 Yuan, Keeps at Neutral	24-07-23	MT
Nomura Adjusts Jiangsu Hengrui Medicine’s Price Target to 51.12 Yuan From 49.24 Yuan, Keeps at Neutral	24-03-15	MT
Nomura Adjusts Jiangsu Hengrui Medicine's Price Target to 49.24 Yuan From 50.19 Yuan, Keeps at Neutral	23-10-17	MT

Jiangsu Hengrui Medicine Co., Ltd. Stock

Equities

600276

CNE0000014W7

Pharmaceuticals

Valuation: Jiangsu Hengrui Medicine Co., Ltd.

Chart: Jiangsu Hengrui Medicine Co., Ltd.

Latest news: Jiangsu Hengrui Medicine Co., Ltd.

Analysts' recommendations: Jiangsu Hengrui Medicine Co., Ltd.

Press Releases: Jiangsu Hengrui Medicine Co., Ltd.

News in other languages: Jiangsu Hengrui Medicine Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Jiangsu Hengrui Medicine Co., Ltd.

ETFs: Jiangsu Hengrui Medicine Co., Ltd.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly revenue - Rate of surprise

Medicilon and Hengrui Pharma Deepen Strategic Collaboration to Support Innovation in ADCs, Small Nucleic Acids, and CGT Drugs	24-08-01	AQ
Elevar Therapeutics Reports Plans for Near-Term Resubmission of NDA for First-Line Treatment Option for Unresectable Hepatocellular Carcinoma Following Type a FDA Meeting	24-07-10	AQ
Triple Negative Breast Cancer Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)	24-05-14	AQ
Mycovia Pharmaceuticals, Inc. Announces Partner Jiangsu Hengrui Pharmaceuticals Co., Ltd's Commercial Launch of VIVJOA Capsules for the Treatment of Severe Vulvovaginal Candidiasis in China	24-02-08	AQ
Triple Negative Breast Cancer Pipeline, FDA Approvals, Clinical Trials Assessment, Companies 2023 \| Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., and others.	23-12-05	AQ

MÄRKTE ASIEN/Börsen in China von staatlichen Maßnahmen gestützt	24-02-06
MÄRKTE ASIEN/China-Börsen von staatlichen Maßnahmen gestützt	24-02-06
Wordt de CSI A50 de beste Chinese index?	24-01-05
¿Se convertirá el CSI A50 en el mejor índice chino?	24-01-03
Morning Briefing - Markt Schweiz	23-11-01

1 day	+1.37%
1 week	+5.42%
Current month	-1.68%
1 month	-2.42%
3 months	-10.60%
6 months	+6.87%
Current year	-1.68%

Director	Title	Age	Since
Hong Bin Dai CEO	Chief Executive Officer	49	2022-05-04
Jian Jun Liu DFI	Director of Finance/CFO	48	2021-11-18
Yu Xu CMP	Compliance Officer	33	2021-05-31

Manager	Title	Age	Since
Jie Ping Sun BRD	Director/Board Member	55	2020-01-15
Hong Bin Dai BRD	Director/Board Member	49	2020-01-15
Piao Yang Sun CHM	Chairman	66	2021-07-07

Name	Weight	1st Jan change	Investor Rating
KRANESHARES MSCI ALL CHINA HEALTH CARE INDEX UCITS ETF - USD	4.18%	-20.08%	-
KRANESHARES EMERGING MARKET HEALTHCARE INDEX ETF - DISTRIBUTING - USD	3.73%	-14.14%
GLOBAL X CHINA DISRUPTION ETF - USD	1.74%	-9.86%	-

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
JIANGSU HENGRUI MEDICINE CO., LTD.	+1.37%	+5.42%	+8.98%	-1.23%	38.77B
ELI LILLY AND COMPANY	+0.74%	-1.33%	+16.50%	+202.39%	653B
JOHNSON & JOHNSON	+0.75%	+2.54%	-8.64%	-9.97%	354B
NOVO NORDISK A/S	+4.06%	-2.92%	-20.86%	+82.16%	341B
ABBVIE INC.	+1.18%	-1.18%	+4.89%	+31.44%	303B
MERCK & CO., INC.	-1.02%	-2.09%	-18.31%	+21.99%	248B
ROCHE HOLDING AG	+0.73%	+1.94%	+8.35%	-25.55%	236B
ASTRAZENECA PLC	+2.12%	+3.52%	+3.91%	+25.73%	206B
NOVARTIS AG	+0.51%	-0.60%	-5.12%	+12.14%	197B
PFIZER, INC.	+0.70%	+0.55%	-6.20%	-49.70%	149B
Average	+1.12%	-1.92%	-1.65%	+28.94%	272.63B
Weighted average by Cap.	+1.13%	-3.50%	-0.46%	+60.87%

	2024 *	2025 *
Net sales	27.11B 3.71B 3.57B 3.37B 3.02B 5.32B 320B 5.93B 40.96B 15.18B 132B 13.93B 13.64B 578B	29.73B 4.07B 3.92B 3.7B 3.31B 5.83B 351B 6.5B 44.91B 16.64B 145B 15.27B 14.96B 634B
Net income	6.04B 827M 795M 751M 672M 1.18B 71.28B 1.32B 9.12B 3.38B 29.41B 3.1B 3.04B 129B	6.58B 902M 867M 819M 733M 1.29B 77.73B 1.44B 9.94B 3.69B 32.07B 3.38B 3.31B 140B
Net Debt	-23.74B -3.25B -3.13B -2.95B -2.64B -4.66B -280B -5.19B -35.86B -13.29B -116B -12.2B -11.94B -506B	-29.14B -3.99B -3.84B -3.62B -3.25B -5.72B -344B -6.37B -44.02B -16.31B -142B -14.97B -14.66B -621B